General
Preferred name
dextropropoxyphene
Synonyms
Levopropoxyphene napsylate, anhydrous ()
Levopropoxyphene napsylate anhydrous ()
Levopropoxyphene Napsylate ()
Darvon-N ()
PROPOXYPHENE ()
PROPOXYPHENE HYDROCHLORIDE ()
PROPOXYPHENE NAPSYLATE ()
(+)-Propoxyphene-d11 (hydrochloride) (CRM) ()
J5.928E ()
Dextropropoxifeno ()
Propoxyphene, d- ()
Algafan ()
Dextropropoxyphen ()
D-propoxyphene ()
SK-65 ()
Depromic ()
IDS-ND-004(SECT.2) ()
Propoxyphene hcl ()
Doloxene ()
Femadol ()
Proxagesic ()
Prophene 65 ()
Propoxyphene hydrochloride component of wygesic ()
Harmar ()
Propoxyphene Hydrochloride 65 ()
Deprancol ()
Propoxyphene hydrochloride cii ()
Kesso-Gesic ()
Dextro propoxyphene hydrochloride ()
Dextropropoxyphene hydrochloride ()
Propoxyphene hydrochloride component of dolene ap-65 ()
Algaphan ()
Propoxyphene hydrochloride component of darvocet ()
Dextropropoxiphene Chloride ()
Darvon ()
Propoxyphene hydrochloride component of darvon compound ()
Dolene ()
Propoxyphene napsylate monohydrate ()
Dextropropoxyphene napsilate ()
Propoxyphene napsylate cii ()
D-propoxyphene napsylate hydrate ()
(+)-Propoxyphene-d5 (hydrochloride) (CRM) ()
P&D ID
PD009225
CAS
469-62-5
21086-94-2
17140-78-2
26570-10-5
1639-60-7
Tags
drug
available
Approved by
FDA
First approval
1957
1971
Drug indication
Pain
Drug Status
approved
withdrawn
investigational
illicit
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE The major route of metabolism is cytochrome CYP3A4 mediated N-demethylation to norpropoxyphene, which is excreted by the kidneys. ; In 48 hours, approximately 20% to 25% of the administered dose of propoxyphene is excreted via the urine, most of which is free or conjugated norpropoxyphene.
DESCRIPTION Dextropropoxyphene is principally an opioid analgesic. Chemically it is an optical isomer of levopropoxyphene (the (2R,3S) optical isomer with PubChem CID 200742); dextropropoxyphene being the (2S,3R) enantiomer. Marketing in Europe and the US has been discontinued due to concerns of fatal overdoses and heart arrhythmias. (GtoPdb)
Compound Sets
12
Cayman Chemical Bioactives
20815
19693
ChEMBL Approved Drugs
CHEMBL1213351
CHEMBL1237104
CHEMBL3989716
ChEMBL Drugs
CHEMBL1213351
CHEMBL1237104
CHEMBL3989716
DrugBank
DB00647
DrugBank Approved Drugs
DB00647
DrugCentral
844
DrugCentral Approved Drugs
844
DrugMAP
DM23HCX
DMMSOLA
DrugMAP Approved Drugs
DM23HCX
DMMSOLA
Guide to Pharmacology
7593
Other bioactive compounds
Withdrawn 2.0
w160
External IDs
67
Properties
(calculated by RDKit )
Molecular Weight
339.22
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
8
Ring Count
2
Aromatic Ring Count
2
cLogP
4.28
TPSA
29.54
Fraction CSP3
0.41
Chiral centers
2.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
ATC
N02AC04
Toxicity type
cardiovascular
Therapeutic Class
Analgesics
Neurology Agents
Source data